You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

30 Results
Guidelines and Advice
Status: Archived
ID: 3-8-1
Apr 2013
Guidelines and Advice
Status: Archived
ID: 4-10
Aug 2013
Guidelines and Advice
Status: Archived
ID: 5-1
Apr 2013
Guidelines and Advice
Status: Archived
ID: 6-15
Dec 2013
Guidelines and Advice
Status: Archived
ID: 9-2
Nov 2013
Guidelines and Advice
Status: Archived
ID: 6-17
Nov 2013
Guidelines and Advice
Status: Archived
ID: 6-2
Version: 2
Aug 2013
Guidelines and Advice
Status: Archived
ID: 9-7
Mar 2013
Guidelines and Advice
Status: Archived
ID: 12-8
Version: 2
Jun 2013
Statistical Reports
Mar 2013
Regimen
Cancer Type:
Central Nervous System
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative, Palliative
Funding:
ODB - General Benefit
    procarbazine
ODB - General Benefit
    lomustine
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
lomustine,
procarbazine,
vinCRIStine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) - As Part of the MATRix Regimen in Newly Diagnosed Previously Untreated PCNSL
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab,
methotrexate,
cytarabine,
thiotepa
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2023

Pages